GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO. METREX involved patients with a range of ...
“Following physician and patient experience with Nucala in severe eosinophilic asthma, we are thrilled that the FDA has expanded the use of this medicine to patients with EGPA, another ...
Hosted on MSN4mon
GSK's Respiratory Drug Nucala Meets Goal in COPD StudyData from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful ...
Hosted on MSN1mon
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPDImage Source: Zacks Investment Research GSK’s regulatory filing seeking the approval of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype was ...
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved ... indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic ...
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal ... for the treatment of adult patients with chronic rhinosinusitis with nasal polyps ...
“We are delighted that Nucala has been approved in China as a treatment for CRSwNP, a chronic condition for which new and effective treatments are needed. “Patients now have a non-surgical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback